Latest Commercialization News

Aldoro Resources has reported significant progress at its Kameelburg REE-Niobium Carbonatite Project in Namibia, confirming a substantial polymetallic discovery and expanding its Phase I drilling program with full funding secured.

Hexima Limited reported a stable cash position of $1.55 million at quarter-end, with a modest $87,000 net cash outflow from operations. The biotech company continues to explore strategic opportunities while maintaining a strong funding runway.

Skin Elements Limited advances its natural biotechnology products with ECO-Nurture trials concluding and SuprCuvr disinfectant gaining traction, supported by a successful $656k capital raise.

Clean TeQ Water Limited reported strong operational progress in Q3 FY25, advancing key projects like PHOSPHIX and Heathgate uranium plant commissioning, while improving cash receipts and securing major contracts.

Cadoux Limited has made significant progress in its High Purity Alumina and Minhub rare earth projects during Q1 2025, advancing engineering studies, securing key contracts, and strengthening ESG initiatives while preparing for commercialisation.

D3 Energy’s latest quarterly report reveals a promising new helium production province at its ER315 permit, alongside expanded exploration permits and preparations for a key Production Right application.

Mustera Property Group advances its McCabe Street apartment project with a planned sales launch in Q3 2025, while settling $4.5 million in sales at Forbes Residences during the March quarter.

Nimy Resources has defined a high-grade gallium Exploration Target in Western Australia and secured strategic partnerships to support supply to the US Department of Defense, positioning itself strongly in the critical minerals sector.

EVE Health Group has executed a binding agreement to acquire Australian biotech Nextract, targeting rapid-onset treatments in the $16 billion global erectile dysfunction and dysmenorrhea markets. The acquisition, supported by a $1.5 million capital raise and share consolidation, marks a strategic shift into regulated pharmaceutical channels.

Ava Risk Group reported a solid Q3 FY2025 with $6.5 million in sales orders and a key new contract with Telstra for subsea cable protection, setting the stage for accelerated growth in Q4.

Dotz Nano has successfully demonstrated its DotzEarth direct air capture technology at lab scale and secured a A$4 million investment to advance to real-world pilot testing, signaling growing momentum in its carbon capture ambitions.

Clarity Pharmaceuticals reports a robust cash position and strategic refocus on its lead prostate cancer asset, Cu-SAR-bisPSMA, supported by multiple FDA Fast Track designations and advancing clinical trials.